- Home
- PMEC vs BTAI Comparison
PMEC vs BTAI Comparison
Compare PMEC & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- BTAI
- Stock Information
- Founded
- PMEC 1984
- BTAI 2017
- Country
- PMEC Singapore
- BTAI United States
- Employees
- PMEC N/A
- BTAI N/A
- Industry
- PMEC
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- BTAI Health Care
- Exchange
- PMEC Nasdaq
- BTAI Nasdaq
- Market Cap
- PMEC 56.9M
- BTAI 48.3M
- IPO Year
- PMEC 2023
- BTAI 2018
- Fundamental
- Price
- PMEC $1.88
- BTAI $2.17
- Analyst Decision
- PMEC
- BTAI Buy
- Analyst Count
- PMEC 0
- BTAI 5
- Target Price
- PMEC N/A
- BTAI $32.80
- AVG Volume (30 Days)
- PMEC 126.7K
- BTAI 1.0M
- Earning Date
- PMEC 01-01-0001
- BTAI 11-13-2025
- Dividend Yield
- PMEC N/A
- BTAI N/A
- EPS Growth
- PMEC N/A
- BTAI N/A
- EPS
- PMEC N/A
- BTAI N/A
- Revenue
- PMEC $74,349,000.00
- BTAI $868,000.00
- Revenue This Year
- PMEC N/A
- BTAI N/A
- Revenue Next Year
- PMEC N/A
- BTAI $614.78
- P/E Ratio
- PMEC N/A
- BTAI N/A
- Revenue Growth
- PMEC 2.52
- BTAI N/A
- 52 Week Low
- PMEC $0.54
- BTAI $1.17
- 52 Week High
- PMEC $2.44
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- PMEC 49.65
- BTAI 36.64
- Support Level
- PMEC $1.67
- BTAI $2.14
- Resistance Level
- PMEC $2.30
- BTAI $2.46
- Average True Range (ATR)
- PMEC 0.21
- BTAI 0.17
- MACD
- PMEC -0.02
- BTAI 0.01
- Stochastic Oscillator
- PMEC 35.00
- BTAI 8.61
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.